<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; OSDD</title>
	<atom:link href="http://www.tapanray.in/tag/osdd/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Making &#8216;National Policy For Rare Diseases&#8217; More Meaningful With &#8216;Orphan Drugs Act&#8217;</title>
		<link>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act</link>
		<comments>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/#comments</comments>
		<pubDate>Mon, 03 Jul 2017 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CSTR]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[highlights]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8305</guid>
		<description><![CDATA[In November 2016, while hearing a related case, the Delhi High Court reportedly directed the Union Government to finalize and implement a policy on rare diseases, with a provision for free treatment with the expensive medications, as will be required by &#8230; <a href="http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Potential Game Changer For Pharma R&amp;D</title>
		<link>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-potential-game-changer-for-pharma-rd</link>
		<comments>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/#comments</comments>
		<pubDate>Mon, 10 Feb 2014 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abdul]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kalam]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[OHE]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viehbacher]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4974</guid>
		<description><![CDATA[The ghost of ‘Patent Cliff’ has been haunting the ‘Big Pharma’ since quite some time. This situation has been further aggravated by cost containment pressures of various Governments both in the developed and the emerging markets together with contentious issues &#8230; <a href="http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Open Innovation: Quo Vadis, Pharmaceutical R&amp;D?</title>
		<link>http://www.tapanray.in/open-innovation-quo-vadis-pharmaceutical-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=open-innovation-quo-vadis-pharmaceutical-rd</link>
		<comments>http://www.tapanray.in/open-innovation-quo-vadis-pharmaceutical-rd/#comments</comments>
		<pubDate>Mon, 04 Jul 2011 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quo]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[Vadis]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=234</guid>
		<description><![CDATA[Is the Pharmaceutical R&#38;D moving from the traditional models to much less uncharted frontiers? Perhaps towards this direction, in November, 2010 in a report titled, “Open Source Innovation Increasingly Being Used to Promote Innovation in the Drug Discovery Process and &#8230; <a href="http://www.tapanray.in/open-innovation-quo-vadis-pharmaceutical-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/open-innovation-quo-vadis-pharmaceutical-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>From Cross-Licensing to ‘Patent Pools’ and&#8230; India: Will there be a ground swell?</title>
		<link>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell</link>
		<comments>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/#comments</comments>
		<pubDate>Mon, 23 May 2011 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Cross]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pools]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[swell]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Will]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=254</guid>
		<description><![CDATA[Since many years, the global pharmaceutical industry has been making effective commercial use of cross-licensing, however, by and large, the industry still does not seem to be quite in favor of  &#8216;Patent Pools&#8217; for various reasons. The ‘Patent Pool’, as &#8230; <a href="http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Open Source Drug Discovery (OSDD) initiative for the tropical diseases by CSIR and cancer by GlaxoSmithKline deserves a big applaud and support from all concerned.</title>
		<link>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned</link>
		<comments>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/#comments</comments>
		<pubDate>Thu, 03 Dec 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[applaud]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[concerned]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[deserves]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool. Open]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[tropical]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=709</guid>
		<description><![CDATA[As the name suggest the ‘Open Source Drug Discovery (OSDD)’ is an open source code model of discovering a New Chemical Entity (NCE) or a New Molecular Entity (NME). In this model all data generated related to the discovery research will be &#8230; <a href="http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Pool’ – is GSK setting a new trend for the global pharmaceutical industry?</title>
		<link>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 18 May 2009 00:30:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=884</guid>
		<description><![CDATA[On February 13, 2009, The Guardian reported that Andrew Witty, CEO of GlaxoSmithKline (GSK) announced some significant changes to the way his company will operate in the developing countries of the world. GSK, as Witty said, will: • “Cut its &#8230; <a href="http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Orphan Drugs’ for ‘Orphan Diseases’ – is ‘Open Source Drug Discovery (OSDD)’ platform for discovery research the way forward?</title>
		<link>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward</link>
		<comments>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/#comments</comments>
		<pubDate>Sun, 22 Feb 2009 09:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=962</guid>
		<description><![CDATA[To meet the unmet needs of common and dreaded diseases intensive R&#38;D activities are being undertaken by the Pharmaceutical Industry, the world over. At the same time, a percentage of human population, however small, also suffers from some rare diseases, &#8230; <a href="http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
